The earnings call highlighted strong international revenue growth and significant progress in expanding screening and treatment capacity. However, these positives were offset by the downward revision of revenue guidance, decline in gross margins, and slower than expected U.S. revenue growth due to capacity constraints and evolving priorities. The overall sentiment reflects a balanced view with positive international performance but challenges in U.S. market execution.

Company Guidance

During the second quarter of 2025, Pulmonx reported revenue of $23.9 million, with international markets contributing $9.1 million, significantly above expectations due to robust growth across key regions. However, U.S. revenue totaled $14.7 million, reflecting slower-than-expected growth in procedure volumes. This led to a revision of the full-year 2025 revenue guidance from an initial range of $96 million to $98 million down to $90 million to $92 million. The company continues to invest in its growth initiatives, including direct-to-patient outreach and AI-powered screening tools like LungTraX Detect, but noted that these programs are taking longer than anticipated to convert into revenues. Pulmonx remains optimistic about its long-term growth, driven by strong international performance and emerging opportunities in the U.S. market.

Strong International Revenue Growth

International revenue for the second quarter of 2025 was a record $9.1 million, a 32% increase compared to $6.9 million in the same period last year and a 27% increase on a constant currency basis.

Significant Increase in StratX Referrals

StratX referrals rebounded to record levels in June and July, indicating a positive response to the initiatives deployed.

Expansion of Screening Capacity

In Q2, 12 new screening centers were opened and 26 new physicians were trained, creating new points of patient access and expanding treatment capacity.

Pulmonx (LUNG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LUNG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.42 / -	-0.36	―	―	―
Jul 30, 2025	2025 (Q2)	-0.39 / -0.38	-0.39	2.56% (+0.01)	―
Apr 30, 2025	2025 (Q1)	-0.40 / -0.36	-0.36	0.00% (0.00)	―
Feb 19, 2025	2024 (Q4)	-0.45 / -0.33	-0.36	8.33% (+0.03)	―
Oct 30, 2024	2024 (Q3)	-0.45 / -0.36	-0.39	7.69% (+0.03)	―
Jul 31, 2024	2024 (Q2)	-0.42 / -0.39	-0.43	9.30% (+0.04)	―
May 01, 2024	2024 (Q1)	-0.47 / -0.36	-0.42	14.29% (+0.06)	―
Feb 21, 2024	2023 (Q4)	-0.41 / -0.36	-0.38	5.26% (+0.02)	―
Oct 30, 2023	2023 (Q3)	-0.43 / -0.39	-0.38	-2.63% (-0.01)	―
Aug 02, 2023	2023 (Q2)	-0.44 / -0.43	-0.4	-7.50% (-0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LUNG Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$3.15	$1.84	-41.59%
Apr 30, 2025	$4.83	$3.77	-21.95%
Feb 19, 2025	$6.64	$8.78	+32.23%
Oct 30, 2024	$6.79	$6.25	-7.95%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pulmonx Corporation (LUNG) report earnings?

Pulmonx Corporation (LUNG) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).

What is Pulmonx Corporation (LUNG) earnings time?

Pulmonx Corporation (LUNG) earnings time is at Oct 29, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LUNG EPS forecast?

LUNG EPS forecast for the fiscal quarter 2025 (Q3) is -0.42.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing